natgillin/translations-raw huggingface dataset:
lægens vejledning til ordination
Physician’s guides to prescribing
Lægens vejledning til ordination bør være specifik for indikationen og indeholde følgende centrale budskaber:
The physician’s guides to prescribing should be indication specific and contain the following key messages:
Lægens vurdering af sværhedsgrad af sygdommen ved baseline
Physician Rating of Severity at Baseline
Lægeovervågning er nødvendig under undersøgelsen, og det anbefales at anlægge i.v.-adgang (venflon/butterfly) et fleksibelt kateter à demeure.
During the examination, supervision by a physician is necessary and insertion of a flexible in-dwelling catheter is recommended.
Lægeovervågning er nødvendig under undersøgelsen, og det anbefales at anlægge i.v.-adgang (venflon/butterfly).
During the examination, supervision by a physician is necessary and insertion of a flexible in-dwelling catheter is recommended.
Læger bør afveje risici versus fordele ved ordination af Sycrest til patienter med Parkinsons sygdom eller Lewy Body-demens, da begge grupper kan have øget risiko for Malignt Neuroleptisk Syndrom samt have en øget følsomhed for antipsykotika.
Physicians should weigh the risks versus the benefits when prescribing Sycrest to patients with Parkinson’s disease or dementia with Lewy Bodies (DLB) since both groups may be at increased risk of neuroleptic malignant syndrome as well as having an increased sensitivity to antipsychotics.
Læger bør konsultere aktuelle retningslinjer for behandling af hiv for optimal kontrol af hiv-infektion hos patienter med samtidig infektion med hepatitis B-virus (HBV).
Physicians should refer to current HIV treatment guidelines for the optimal management of HIV infection in patients co-infected with hepatitis B virus (HBV).
Læger bør nøje afveje risici og fordele ved ordination af Xeplion til patienter med Parkinsons sygdom eller Lewy body-demens (DLB), da begge grupper kan have en øget risiko for udvikling af malignt neuroleptikasyndrom samt have en øget følsomhed over for antipsykotika.
Physicians should weigh the risks versus the benefits when prescribing Xeplion to patients with Parkinson’s Disease or Dementia with Lewy Bodies (DLB) since both groups may be at increased risk of Neuroleptic Malignant Syndrome as well as having an increased sensitivity to antipsychotics.
Læger bør opfordre patienterne til at rapportere alle bekymrende tanker, følelser eller depressive symptomer, de måtte have på et hvilket som helst tidspunkt.
Physicians should encourage patients to report any distressing thoughts or feelings or depressive symptoms at any time.
Læger bør overveje PTLD som differentialdiagnose hos patienter med nye eller forværrede neurologiske, kognitive eller adfærdsmæssige objektive fund eller symptomer.
Physicians should consider PML in the differential diagnosis in patients with new or worsening neurologic, cognitive or behavioural signs or symptoms.
Læger bør overvåge patienterne for væskeansamlinger, da sådanne kan føre til hjerteinsufficiens (når hjertet ikke er i stand til at pumpe tilstrækkeligt blod rundt i kroppen).
Doctors should monitor patients for fluid retention as this can lead to heart failure (an inability of the heart to pump enough blood around the body).
Læger bør overvåge patienternes vægt, og når det er relevant opfordre til øget kalorieindtag, hvis vægttabet betragtes som klinisk signifikant.
Physicians should monitor patients’ weight, and when appropriate encourage increased caloric intake if weight loss is considered to be of clinical significance.
Læger bør tage PTLD i betragtning som differentialdiagnose hos patienter med nye eller forværrede neurologiske, kognitive eller adfærdsmæssige objektive fund eller symptomer.
Physicians should consider PTLD in the differential diagnosis in patients with new or worsening neurologic, cognitive or behavioural signs or symptoms.
Læger bør udvise forsigtighed ved administration af Ilaris til patienter med aktuel infektion, anamnestiske oplysninger om tilbagevendende infektioner, eller underliggende tilstande, der kan prædisponere for infektioner.
Physicians should exercise caution when administering Ilaris to patients with infections, a history of recurring infections, or underlying conditions which may predispose them to infections.
Læger bør udvise forsigtighed ved brug af Benepali til patienter med kongestiv hjerteinsufficiens (CHF).
Physicians should use caution when using Benepali in patients who have congestive heart failure (CHF).
Læger bør udvise forsigtighed ved brug af Enbrel i patienter med hjerteinsufficiens (CHF).
Physicians should use caution when using Enbrel in patients who have congestive heart failure (CHF).
Læger bør udvise forsigtighed ved brug af Enbrel i patienter med kongestiv hjerteinsufficiens (CHF).
Physicians should use caution when using Enbrel in patients who have congestive heart failure (CHF).
Læger er opmærksomme på denne bivirkning og har akutberedskab klar til brug i sådanne tilfælde
Doctors are aware of this possibility and have emergency treatment available for use in such cases.
Læger henvises til produktinformationen for disse lægemidler.
Physicians should refer to the individual prescribing information for these medicinal products.
Læger og sundhedpersonale anmodes om at indberette alle formodede bivirkninger via det nationale rapporteringssystem anført i Appendiks V.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedsgpersonale anmodes om at indberette alle formodede bivirkninger via det nationale rapporteringssystem anført i Appendiks V
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedsgpersonale anmodes om at indberette alle formodede bivirkninger via det nationale rapporteringssystem anført i Appendiks V.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale anmodes om at indberette alle formoded bivirkninger via det nationale rapporteringssystem anført i Appendiks V.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale anmodes om at indberette alle formodede bivirkninger det nationale rapporteringssystem anført i Appendiks V.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale anmodes om at indberette alle formodede bivirkninger nationale rapporteringssystem anført i Appendiks V.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale anmodes om at indberette alle formodede bivirkninger til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks V
You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Læger og sundhedspersonale anmodes om at indberette alle formodede bivirkninger til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks V.
You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Læger og sundhedspersonale anmodes om at indberette alle formodede bivirkninger til Sundhedsstyrelsen via det nationale rapporteringssystem anført i Appendiks V.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V
Læger og sundhedspersonale anmodes om at indberette alle formodede bivirkninger via det nationale rapporteringssystem anført Appendiks V.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V*.
Læger og sundhedspersonale anmodes om at indberette alle formodede bivirkninger via det nationale rapporteringssystem anført Appendiks V.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale anmodes om at indberette alle formodede bivirkninger via det nationale rapporteringssystem anført i 3A1TU ppendiks V.U31T
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale anmodes om at indberette alle formodede bivirkninger via det nationale rapporteringssystem anført i Appendiks V.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system in Appendix V.
Læger og sundhedspersonale anmodes om at indberette alle formodede bivirkninger via det nationale rapporteringssystem anført i Appendiks V.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V:
Læger og sundhedspersonale anmodes om at indberette alle formodede bivirkninger via det nationale rapporteringssystem anført i Appendiks V.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. listed in Appendix V.
Læger og sundhedspersonale anmodes om at indberette alle formodede bivirkninger via det nationale rapporteringssystem anført i Appendiks V.
Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme, website: www.mhra.gov.uk/yellowcard.
Læger og sundhedspersonale anmodes om at indberette alle formodede bivirkninger via det nationale rapporteringssystem anført i Appendiks V.
Healthcare professionols are asked to report any suspected adverse reactions via the national reporting sytem listed in Appendix V.
Læger og sundhedspersonale anmodes om at indberette alle formodede bivirkninger via det nationale rapporteringssystem anført i AppendiksV.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale anmodes om at indberette alle formodede bivirkninger via det nationale rapporteringssystem anført i Appendix V.*
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale anmodes om at indberette alle formodede bivirkninger via det nationale rapporteringssystem anført i i Appendiks V.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V
Læger og sundhedspersonale anmodes om at indberette alle formodede bivirkninger via det nationale rapporteringssystem anført iAppendiks V.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale anmodes om at indberette alle formodede bivirkninger via det nationale rapporteringssystem angivet i Appendiks V.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale anmodes om at indberette alle formodede bivirkninger via det nationale rapporteringssystem.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale anmodes om at indberette alle formodede bivirkninger via Sundhedsstyrelsens netsted www.meldenbivirkning.dk, på mail til sst@sst.dk eller via brev til Sundhedsstyrelsen, Axel Heides Gade 1, 2300 København S.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale anmodes om at indberette alle formodede bivirkninger via www.meldenbivirkning.dk eller via Lægemiddelstyrelsen, Axel Heides Gade 1, DK-2300 København S,
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale anmodes om at indberette alle formodede bivirkninger via www.meldenbivirkning.dk.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale anmodes om at indberette alle formodede bivirkninger via: det nationale rapporteringssystem anført i Appendiks V*.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale anmodes om at indberette alle formodede bivirkninger via: det nationale rapporteringssystem angivet i Appendiks V.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale anmodes om at indberette alle formodede bivirkninger.
Healthcaare professionals are asked to report any suspected adverse reactions.
Læger og sundhedspersonale anmodes om at indberette alle formodedee bivirkninger via det nationale rapporteringssystem anført i Appendiks V.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale anmodes om at indberette alle mistænkte bivirkning via det nationale repporteringssystem anført i Appendiks V.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale anmodes om at indberette alle mistænkte bivirkninger direkte til Sundhedsstyrelsen på www.meldenbivirkning.dk, eller ved at kontakte Sundhedsstyrelsen via mail på sst@sst.dk eller med almindeligt brev til Sundhedsstyrelsen, Axel Heides Gade 1, 2300 København S.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale anmodes om at indberette alle mistænkte bivirkninger via
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale anmodes om at indberette alle mistænkte bivirkninger via det nationale indberetningssystem anført i Appendiks V.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V
Læger og sundhedspersonale anmodes om at indberette alle mistænkte bivirkninger via det nationale rapporteringssystem anført Appendiks V.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale anmodes om at indberette alle mistænkte bivirkninger via det nationale rapporteringssystem anført i Appendiks V*.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V*.
Læger og sundhedspersonale anmodes om at indberette alle mistænkte bivirkninger via det nationale rapporteringssystem anført i Appendix V.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale anmodes om at indberette alle mistænkte bivirkninger via det nationale rapporteringssystem anført i i Appendiks V.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale anmodes om at indberette alle mistænkte bivirkninger via det nationale rapporteringssystem anført i { HYPERLINK "http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC50013975 2.doc" }.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V*.
Læger og sundhedspersonale anmodes om at indberette alle mistænkte bivirkninger via det nationale rapporteringssystem anført iAppendiks V.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed inAppendix V..
Læger og sundhedspersonale anmodes om at indberette alle mistænkte bivirkninger via det nationale rapporteringssystem som angivet i Bilag V.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale anmodes om at indberette alle mistænkte bivirkninger via på www.meldenbivirkning.dk eller via Sundhedsstyrelsen, Axel Heides Gade 1, DK-2300 København S, e-mail: sst@sst.dk.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale anmodes om at indberette alle mistænkte bivirkninger via www.meldenbivirkning.dk, eller ved at kontakte Sundhedsstyrelsen via mail på sst@sst.dk eller med almindeligt brev til Sundhedsstyrelsen, Axel Heides Gade 1, 2300 København S.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale anmodes om at indbrette alle formodede bivirkninger via det nationale rapporteringssystem anført i Appendiks V*.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale anmodes om at ndberette alle formodede bivirkninger via det nationale rapporteringssystem anført i Appendiks V.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale opfordres til at indberette alle formodede bivirkninger via det nationale indberetningssystem, der er anført i appendiks V
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Læger og sundhedspersonale skal gøres opmærksom på anvendelse af antiarytmika før og efter BRINAVESS.
Alert HCP for use of antiarrhythmic drugs (AADs) prior to or after BRINAVESS.
Læger og sundhedspersonale skal gøres opmærksom på behovet for forholdsregler, når BRINAVESS anvendes til hæmodynamisk stabile patienter med venstresidig hjerteinsufficiens NYHA I og NYHA II, og behovet for tæt monitorering af patienter med valvulær hjertesygdom.
Alert HCP about the need of precautions when using BRINAVESS in haemodynamically stable patients with congestive heart failure NYHA I and NYHA II and the need to monitor patients with valvular heart disease closely.
Læger og sundhedspersonale skal gøres opmærksom på bivirkninger, der kan forekomme efter administration af BRINAVESS herunder hypotension, bradykardi, atrieflagren eller ventrikulær arytmi.
Alert HCP for adverse reactions, which may occur after BRINAVESS administration, including hypotension, bradycardia, atrial flutter, or ventricular arrhythmia.
Læger og sundhedspersonale skal gøres opmærksom på kontraindikationerne for BRINAVESS:
Alert HCP on BRINAVESS contraindications:
Læger og sundhedspersonale skal gøres opmærksom på særlige advarsler og forsigtighedsregler for BRINAVESS hos patienter med klinisk betydningsfuld valvulær stenose, hypertrofisk obstruktiv kardiomyopati, restriktiv kardiomyopati eller konstriktiv perikaridit, tidligere dokumenteret venstre ventrikel ejektionsfraktion ≤35%, fremskreden leverinsufficiens.
Alert HCP about BRINAVESS special warnings and precautions in patients with, clinically meaningful valvular stenosis, hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, or constrictive pericarditis, previously documented LVEF ≤ 35%, advanced hepatic impairment.
Læger og sundhedspersonaleanmodes om at indberette alle formodede bivirkninger via det nationale rapporteringssystem anført i Appendiks V.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V
Læger og sunhedspersonale anmodes om at indberette alle formodede bivirkninger via det nationale rapporteringssystem anført i Appendiks V*.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V*.
Læger skal derfor udvise forsigtighed, når de administrerer Longuex til patienter med seglcelleanæmi, overvåge hensigtsmæssige kliniske parametre og laboratorieresultater, og de skal være opmærksomme på den mulige forbindelse mellem lipegfilgrastim og forstørret milt og vasookklusiv krise.
Physicians should therefore exercise caution when administering Lonquex in patients with sickle cell anaemia, monitor appropriate clinical parameters and laboratory results and be attentive to the possible association of lipegfilgrastim with splenic enlargement and vaso-occlusive crisis.
Læger skal drøfte, hvor alvorligt hedeslag kan være, i hvilke situationer det kan forekomme, samt hvilke handlinger der skal træffes i tilfælde af tegn eller symptomer, med patienterne og deres omsorgsgivere.
Physicians should discuss with patients and their carers the potential seriousness of heatstroke, situations in which it might arise, as well as action to take in the event of any signs or symptoms.
Læger skal forhøre sig om ethvert tilfælde af pludselig død i en ung alder i familieanamnesen, da dette kan være tegn på medfødt QT-forlængelse.
Physicians should enquire about any known familial history of sudden death at a young age as this may be suggestive of congenital QT prolongation.
Læger skal henholde sig til gældende retningslinjer for hiv-behandling ved håndtering af hiv-infektion hos patienter med samtidig infektion med hepatitis B-virus (HBV) eller hepatitis C-virus (HCV).
Physicians should refer to current HIV treatment guidelines for the management of HIV infection in patients co-infected with hepatitis B virus (HBV) or hepatitis C virus (HCV)
Læger skal regelmæssigt vurdere patienter med kronisk ITP, som stadig har milten for at se, om en operation er nødvendig.
Doctors should also periodically assess patients with chronic ITP who still have a spleen to see if they require surgery.
Læger skal udvise forsigtighed, når de overvejer at behandle med filgrastim hos patienter med seglcellesygdom, og dette bør kun finde sted efter nøje afvejning af mulige risici og fordele.
Physicians should exercise caution when considering the use of filgrastim in patients with sickle cell disease and only after careful evaluation of the potential risks and benefits.
Læger skal være forsigtige, hvis de overvejer kombinationsbehandling med sulfasalazin.
Physicians should use caution when considering combination therapy with sulfasalazine.
Læger skal være forsigtige, når de overvejer brug af Enbrel til patienter, der har en anamnese med tilbagevendende eller kroniske infektioner eller med tilgrundliggende sygdomstilstande, som kan prædisponere patienterne til infektioner, for eksempel fremskreden eller dårligt kontrolleret diabetes.
Physicians should exercise caution when considering the use of Enbrel in patients with a history of recurring or chronic infections or with underlying conditions that may predispose patients to infections such as advanced or poorly controlled diabetes.
Læger skal være opmærksomme på mulig udvikling af pneumoni hos patienter med KOL, da de kliniske tegn på sådanne infektioner ligner symptomerne på KOL-eksacerbationer.
Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of such infections overlap with the symptoms of COPD exacerbations.
Læger skal være opmærksomme på symptomer på infektion eller forværring af Stills sygdom, da dette kan udløse MAS.
Physicians should be attentive to symptoms of infection or worsening of Still’s disease, as these are known triggers for MAS.